Cambridge Centre For Neuropsychiatric Research

Psyomics, a spin-out company from the University of Cambridge co-founded by Professor Sabine Bahn, has designed the Censeo Trial, with the aim to develop and evaluate an online mental health assessment for the differential diagnosis of bipolar disorder I and II, major depressive disorder, general anxiety disorder, insomnia, obsessive compulsive disorder, panic disorder, and social anxiety. The Censeo mental health assessment will also screen for alcohol and substance abuse, d...isordered eating, emotional instability, psychosis, self-harm, suicidality, and trauma, as well as non-clinical symptom reporting for low mood, anxiety, sleep problems, obsessive compulsive disorder, and panic attacks. It is intended that the Censeo online mental health assessment will be reviewed by a psychiatrist who will make a diagnosis from the answered questions for patients presenting with concerns about their mental health in primary care settings.
https://www.psyomics.com/
See More

Data analysis for the Delta Trial is well underway here at the CCNR lab. Our team members have been busy combining your questions sessions with blood spot proteins in order to help distinguish between people with bipolar disorder and major depressive disorder. It is anticipated that the combined test will have the potential to drastically reduce misdiagnosis of bipolar disorder as major depressive disorder, thereby leading to the right treatment faster. Please watch out for regular updates.

CCNR team members are heading to the NIHR MindTech symposium in London on Thursday, 5th Dec! We are looking forward to hearing from fellow researchers and a great line-up of speakers.

The CCNR and Delta Trial Team would like to extend a heartfelt thank you for the generous support from everyone who participated in the Delta Trial.
We would like to make you aware that the Delta Trial will soon be completed and you will no longer be able to log into your account as we are closing the website.
We are in the process of analysing and reviewing all the information we have collected. We will notify you on the CCNR website (http://ccnr.ceb.cam.ac.uk/) and on our ...Facebook and Twitter feeds when we publish the results.
We want to thank you again for participating in the Delta Trial. Your contribution has been invaluable and has allowed us to develop a diagnostic test for mental health concerns. An updated and improved version of the test will be tested in the NHS in 2020.
See More

Can we predict whether individuals will develop depression based on proteomic, sociodemographic, and clinical data? Please take a look at the recent article published by our team: https://www.nature.com/articles/s41398-01 9-0623-2

BBC coverage of our recently published article in Science Advances regarding a novel approach to neuropsychiatric drug discovery based on high-content single cell screening of signalling network responses ex vivo. https://youtu.be/Q6B6Msi3QCg

"A novel approach to neuropsychiatric drug discovery based on high-content single cell screening of signalling network responses ex vivo. Please take a look at recent article published by our team: https://advances.sciencemag.org/content/5 /5/eaau9093?rss=1"

Recent research by some of our team members examining the association of Insulin resistance with polygenic risk of schizophrenia https://jamanetwork.com/…/jamapsychiatr y/fullarticle/2729423

CCNR supports the work and aims of World Bipolar Day -- spreading awareness and eliminating social stigma are the first steps on the path forward!

This interesting article discusses the need for increased scientific evidence behind mental health apps. We hope to fill this gap with our research! Read more here: https://www.nature.com/articles/s41746-01 9-0093-1

Thank you, Delta Trial participants who have completed six month follow-up questionnaires! Over half of you who have received the link so far have completed one, and for those participants who have not yet received a link -- please keep an eye out for it. This large proportion reflects the altruism and generosity we have seen from participants in all of our trials, for which we are grateful.

Do the existing categories of neuropsychiatric disorders accurately represent the underlying reality of these conditions? This is the question that some of our team members explored in their recent research, which suggests that a spectrum-based model may be more appropriate. That research can be found here: https://www.nature.com/articles/s41380-01 8-0123-4

Hot off the press is CCNR's latest paper, investigating a multimodel statistical approach for biomarker development that uncovered interesting differences between females and males with schizophrenia. Read more here https://www.nature.com/articles/s41398-01 9-0419-4

Proteomics? Mass spectrometry? Biomarkers?!? Defining these terms and explaining why we use these methods to research neuropsychiatric disorders is the focus of a recent paper by some of our lab members, which is accessible here: http://ow.ly/Ayug50kO5jb

We were excited and humbled to have some of our team members invited to give a presentation to the local Bipolar UK group on Monday night. The well-informed questions showed how those living with mental health challenges are the true experts in this field. Thank you Bipolar UK for the invitation! We hope to continue to share our research and hear from the public in the future.

Over the course of the Delta Trial, we have heard from a number of participants with lived experience of mental health challenges. We would like to thank them for contributing their insights over email as well as the feedback questionnaire and ongoing follow-up questionnaires. Please know that we are listening! These valuable suggestions help guide us as we plan out our next steps and research priorities.